Jun 08, 2021 / 08:30PM GMT
John Peyton - SRAX, Inc. - Moderator
Hi, my name is John Peyton, Business Development at Sequire, shareholder insight and acquisitions. I'm here to present Dr. Peter Altman, CEO of BioCardia, Inc. BioCardia is a clinical-stage regenerative medicines company that develops therapeutics for cardiovascular disease. The lead candidate is the CardiAMP cell therapy system for treatment of heart failure, and chronic myocardial ischemia, and allogenic cell therapy for cardiac and pulmonary disease. The company is based in San Carlos, California.
Dr. Altman, over to you.
Peter Altman - BioCardia, Inc. - President & CEO
Thank you, John. So BioCardia has been focused on bringing personalized medicine to cell therapy for cardiovascular disease. Our efforts today are extensive. And I'll detail them trying to stay at the top level.
Here's our standard forward-looking statements. And I'm going to drop off the screen just to essentially enable folks to understand our pipeline opportunities here.
So the primary reason to be interested in BioCardia
BioCardia Inc at LD Micro Microcap Invitational Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
